Pivotal Research Reiterates Buy Rating for Nu Skin Enterprises (NYSE:NUS)

Nu Skin Enterprises (NYSE:NUS)‘s stock had its “buy” rating reaffirmed by investment analysts at Pivotal Research in a research note issued on Wednesday, AnalystRatings.com reports. They currently have a $70.00 price objective on the stock. Pivotal Research’s price target indicates a potential upside of 72.63% from the company’s previous close.

The analysts wrote, “We suspect that NUS management has taken an axe to the outlook to avoid having to cut again.””

Several other research firms have also issued reports on NUS. Citigroup dropped their price objective on Nu Skin Enterprises from $86.00 to $52.00 and set a “buy” rating for the company in a research note on Thursday, July 18th. Zacks Investment Research raised Nu Skin Enterprises from a “sell” rating to a “hold” rating in a research note on Friday, May 3rd. Bank of America reissued an “underperform” rating and set a $52.00 price objective (down previously from $57.00) on shares of Nu Skin Enterprises in a research note on Wednesday, June 19th. DA Davidson lowered Nu Skin Enterprises from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $88.00 to $38.00 in a research note on Wednesday, July 17th. Finally, Jefferies Financial Group lowered Nu Skin Enterprises from a “buy” rating to a “hold” rating and set a $40.00 price objective for the company. in a research note on Wednesday, July 17th. Three investment analysts have rated the stock with a sell rating, three have given a hold rating and four have given a buy rating to the stock. Nu Skin Enterprises has a consensus rating of “Hold” and a consensus target price of $53.25.

NYSE:NUS traded down $1.38 during trading hours on Wednesday, hitting $40.55. 10,620 shares of the company’s stock traded hands, compared to its average volume of 914,218. The company has a market cap of $2.14 billion, a price-to-earnings ratio of 11.56, a P/E/G ratio of 1.05 and a beta of 0.67. Nu Skin Enterprises has a 52 week low of $35.03 and a 52 week high of $85.75. The company has a fifty day moving average of $43.85. The company has a current ratio of 1.86, a quick ratio of 1.10 and a debt-to-equity ratio of 0.44.

Nu Skin Enterprises (NYSE:NUS) last posted its quarterly earnings data on Tuesday, August 6th. The company reported $0.83 earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.83. The company had revenue of $623.50 million during the quarter, compared to analyst estimates of $622.32 million. Nu Skin Enterprises had a return on equity of 24.94% and a net margin of 4.79%. The firm’s quarterly revenue was down 11.5% on a year-over-year basis. During the same quarter last year, the company earned $0.95 earnings per share. As a group, equities research analysts anticipate that Nu Skin Enterprises will post 3.26 earnings per share for the current fiscal year.

A number of hedge funds have recently modified their holdings of the business. BlackRock Inc. lifted its stake in Nu Skin Enterprises by 19.5% during the first quarter. BlackRock Inc. now owns 7,498,023 shares of the company’s stock worth $358,856,000 after purchasing an additional 1,224,725 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in Nu Skin Enterprises by 3.5% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,132,318 shares of the company’s stock worth $69,442,000 after purchasing an additional 38,282 shares during the last quarter. Norges Bank purchased a new position in shares of Nu Skin Enterprises in the fourth quarter worth about $56,136,000. Acadian Asset Management LLC increased its holdings in shares of Nu Skin Enterprises by 29.5% in the first quarter. Acadian Asset Management LLC now owns 615,706 shares of the company’s stock worth $29,466,000 after buying an additional 140,367 shares during the period. Finally, Los Angeles Capital Management & Equity Research Inc. increased its holdings in shares of Nu Skin Enterprises by 6.0% in the second quarter. Los Angeles Capital Management & Equity Research Inc. now owns 576,970 shares of the company’s stock worth $28,456,000 after buying an additional 32,570 shares during the period. 77.24% of the stock is owned by hedge funds and other institutional investors.

Nu Skin Enterprises Company Profile

Nu Skin Enterprises, Inc develops and distributes anti-aging personal care products and nutritional supplements under the Nu Skin and Pharmanex category brands worldwide. It provides skin care systems, including ageLOC Me customized skin care systems, ageLOC Spa systems, and ageLOC LumiSpa skin treatment and cleansing devices; and Epoch products, as well as a range of other cosmetic and personal care products.

Featured Article: What are the benefits of a portfolio tracker?

Analyst Recommendations for Nu Skin Enterprises (NYSE:NUS)

Receive News & Ratings for Nu Skin Enterprises Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nu Skin Enterprises and related companies with MarketBeat.com's FREE daily email newsletter.